<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Discoveries in the first few years of the 21st century have led to an understanding of important interactions between the <z:mp ids='MP_0008912'>nervous</z:mp> system and the <z:mp ids='MP_0001845'>inflammatory response</z:mp> at the molecular level, most notably the <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> (<z:chebi fb="0" ids="15355">ACh</z:chebi>)-triggered, alpha7-nicotinic <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> receptor (alpha7nAChR)-dependent nicotinic anti-inflammatory pathway </plain></SENT>
<SENT sid="1" pm="."><plain>Studies using the alpha7nAChR <z:chebi fb="4" ids="48705">agonist</z:chebi>, <z:chebi fb="164" ids="18723">nicotine</z:chebi>, for the treatment of mucosal <z:mp ids='MP_0001845'>inflammation</z:mp> have been undertaken but the efficacy of <z:chebi fb="164" ids="18723">nicotine</z:chebi> as a treatment for <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> remains debatable </plain></SENT>
<SENT sid="2" pm="."><plain>Further understanding of the nicotinic anti-inflammatory pathway and other endogenous anti-inflammatory mechanisms is required in order to develop refined and specific therapeutic strategies for the treatment of a number of <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> and conditions, including <z:hpo ids='HP_0000704'>periodontitis</z:hpo>, <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e>, and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
</text></document>